Department of Immunology, Allergy and Infectious Diseases, St. George Hospital, University of New South Wales, Sydney, Australia.
Autoimmun Rev. 2012 Sep;11(11):779-80. doi: 10.1016/j.autrev.2011.12.007. Epub 2011 Dec 31.
Vascular thrombosis and/or recurrent miscarriages are the main characteristics defining Antiphospholipid Syndrome (APS). Currently there is no well-defined clinical features and/or laboratory tests that predicts the risk of adverse prognostic outcomes in APS. In this short review, we report the importance of posttranslational modification of beta2 glycoprotein I, the major autoantigen in the APS beta2 glycoprotein I that may, in part, explain possible mechanisms for the generation of auto antibodies to beta2 glycoprotein I. A specific ELISA measuring the level of oxidised beta2 glycoprotein I could be used as a potential new laboratory test - along with other laboratory tests - to more accurately predict the risk of having a clinical event in patients with APS.
血管血栓形成和/或反复流产是定义抗磷脂综合征(APS)的主要特征。目前,尚无明确的临床特征和/或实验室检查可预测 APS 不良预后结局的风险。在这篇简短的综述中,我们报告了翻译后修饰的β2糖蛋白 I 的重要性,β2糖蛋白 I 是 APS 中的主要自身抗原,这可能部分解释了针对β2糖蛋白 I 产生自身抗体的可能机制。一种测量氧化β2 糖蛋白 I 水平的特定 ELISA 可以与其他实验室检查一起用作潜在的新实验室检查,以更准确地预测 APS 患者发生临床事件的风险。